文献速递呼吸衰竭与机械通气

吡非尼酮与尼达尼布比较:CleanUP-IPF 研究的事后分析

Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
PubMed 文献 · Chest · 2023-11-27
一句话结论在 IPF 患者中,尼达尼布组 12 个月 FVC 较吡非尼酮组高 106 mL(95%CI 34-178),但 24 个月时差异减弱,总生存和无计划性呼吸住院无显著差异。

该研究为 CleanUP-IPF 试验(NCT02759120)的事后分析,纳入 513 例随机化 IPF 患者中报告使用吡非尼酮(n=264,65%)或尼达尼布(n=143,35%)的 407 例。采用线性混合效应模型(随机截距和斜率)分析 FVC 随时间变化,校正年龄、性别、吸烟史、冠心病史、基线 FVC 和 12 个月样条项。结果显示尼达尼布组 12 个月访视 FVC 较吡非尼酮组高 106 mL(95%CI 34-178),该差异在 24 个月访视时减弱;两组总生存和无计划性呼吸住院无显著差异。作者认为在临床试验的事后分析中,使用尼达尼布的 IPF 患者 12 个月 FVC 下降较吡非尼酮缓慢。

要点

  • 在 CleanUP-IPF 试验的 407 例报告使用抗纤维化药的 IPF 患者中,尼达尼布组(n=143)12 个月访视 FVC 较吡非尼酮组(n=264)高 106 mL(95%CI 34-178)。
  • 该 FVC 差异在 24 个月访视时减弱。
  • 吡非尼酮组冠心病史比例高于尼达尼布组(34.1% vs 20.3%)。
  • 两组总生存和无计划性呼吸住院无显著差异。
  • 作者认为,在此事后分析中,使用尼达尼布的 IPF 患者 12 个月 FVC 下降较吡非尼酮缓慢。

适用人群与场景

  • 纳入 CleanUP-IPF 试验且入组时报告使用吡非尼酮或尼达尼布的 IPF 患者(n=407),其中吡非尼酮组 n=264(65%),尼达尼布组 n=143(35%)。

研究设计与关键结果

  • 研究类型:CleanUP-IPF 试验(NCT02759120)的事后分析;共 513 例 IPF 患者随机化,其中 407 例报告使用吡非尼酮(n=264,65%)或尼达尼布(n=143,35%)。
  • 主要终点:尼达尼布组 12 个月访视 FVC 较吡非尼酮组高,平均差 106 mL(95%CI 34-178);该差异在 24 个月访视时减弱。
  • 基线特征:吡非尼酮组冠心病史比例高于尼达尼布组(34.1% vs 20.3%)。
  • 次要终点:吡非尼酮组与尼达尼布组的总生存和无计划性呼吸住院无显著差异。

证据类型、等级与局限

  • 证据类型:临床试验的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在此事后分析中,使用尼达尼布的 IPF 患者 12 个月 FVC 下降较吡非尼酮缓慢。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Antifibrotics are effective in slowing FVC decline in idiopathic pulmonary fibrosis (IPF). However, whether antifibrotic type is differentially associated with FVC decline remains inconclusive.

RESEARCH QUESTION: Are there significant differences in 12-month FVC decline between pirfenidone and nintedanib?

STUDY DESIGN AND METHODS: A post hoc analysis was performed using the Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in IPF (CleanUP-IPF) trial (No. NCT02759120). Participants who reported using pirfenidone or nintedanib on enrollment into the trial were in the primary analysis. Spirometry was scheduled at baseline and the 12- and 24-month study visits. Linear mixed-effects models with random intercept and slope were used to examine changes in FVC over time. Models were adjusted for age, sex, smoking history, coronary artery disease history, baseline FVC, and 12-month spline term. Survival and nonelective respiratory hospitalization by antifibrotic type were determined using Cox regression models with adjustment for age, sex, smoking history, coronary artery disease history, and baseline FVC and diffusing capacity for carbon monoxide.

RESULTS: Out of the 513 participants with IPF randomized in the CleanUP-IPF trial, 407 reported using pirfenidone (n = 264, 65%) or nintedanib (n = 143, 35%). The pirfenidone group had more participants with a history of coronary artery disease than the nintedanib group (34.1% vs 20.3%, respectively). Patients treated with nintedanib had a higher 12-month visit FVC than patients treated with pirfenidone (mean difference, 106 mL; 95% CI, 34-178). This difference was attenuated at the 24-month study visit. There were no significant differences in overall survival and nonelective respiratory hospitalization between the pirfenidone- and nintedanib-treated groups.

INTERPRETATION: Patients with IPF who used nintedanib had a slower 12-month FVC decline than pirfenidone in a post hoc analysis of a clinical trial.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Kim JS, Murray S, Yow E, et al. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. Chest. 2023. PMID: 38030064. doi:10.1016/j.chest.2023.11.035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。